SEC Form 4 · accession 0001127602-18-009568
BIOCRYST PHARMACEUTICALS INC · BCRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jon P Stonehouse
Officer — President & CEO · Director
Period of report
Feb 28, 2018
Accepted (ET)
Mar 2, 2018 · 2:23 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000882796
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 28, 2018 | M | 56,949 | $3.26 | A | 698,316 | D | |
| Common StockF1 | Feb 28, 2018 | F | 43,224 | $4.97 | D | 655,092 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Emp. Stock Option (Right to Buy) | $3.26 | Feb 28, 2018 | M | 56,949 | D | Mar 14, 2009 | Mar 14, 2018 | Common Stock | 56,949 | 0 | D |
Explanation of responses
- F1Shares of Common Stock delivered to the Company to satisfy payment of exercise price and tax withholding in connection with stock option exercise.